FDA Advisory Committee to Review NitroMed's Heart-Failure Drug Bidil

The FDA's Cardiovascular and Renal Drugs Advisory Committee will convene in June to discuss NitroMed's investigational heart-failure drug Bidil.

NitroMed submitted a new drug application to the FDA seeking approval to market Bidil as heart-failure treatment for African-Americans. The proposed indication is based on the results of the African-American Heart Failure Trial. The committee will discuss Bidil June 16.

For more information, go to http://www.fda.gov/oc/advisory/accalendar/2005/cder12533dd06151605.html (http://www.fda.gov/oc/advisory/accalendar/2005/cder12533dd06151605.html).